Skip to main content
SOAGY logo

Sartorius AG ADR (SOAGY) Stock Price & Analysis

Sartorius AG ADR (SOAGY) — price $66.15 (+2.72%), as of the Nov 19, 2026 trading session; market cap $22.8B.

Educational signal · not a buy or sell recommendation · How to read this

$66.15 +$1.75 (+2.72%) Market Cap $22.8B

Sartorius AG ADR · SOAGY · Healthcare · Medical - Instruments & Supplies

Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS).

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • WST · West Pharmaceutical Services, Inc. · 92 /100
  • RMD · ResMed Inc. · 95 /100
  • ALC · Alcon Inc. · 80 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$66.15
Change on the day+2.72%
52-week range$46.97–$66.68
Market capitalisation$22.8B—
Price / earnings (trailing)72.88
Shares traded on the day200
Beta (volatility vs the S&P 500)1.56

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $47, high $66, latest $66. $66 $47 high $66 Oct 17, 2025 Nov 19, 2026 · $66 $54Oct 17, 2025$55Oct 31, 2025$54Nov 14, 2025$58Nov 28, 2025$57Dec 12, 2025$58Dec 26, 2025$60Jan 9, 2026$61Jan 23, 2026$57Feb 6, 2026$56Feb 20, 2026$50Mar 6, 2026$47Mar 20, 2026$49Apr 2, 2026$57Apr 17, 2026$51May 1, 2026$48May 15, 2026$57May 29, 2026$53Jun 12, 2026$52Jun 26, 2026$55Jul 10, 2026$50Jul 24, 2026$54Aug 7, 2026$58Aug 21, 2026$55Sep 4, 2026$57Sep 18, 2026$57Oct 2, 2026$58Oct 16, 2026$65Oct 30, 2026$65Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sartorius AG ADR (SOAGY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

2 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Weak
ROE Neutral
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sartorius AG ADR (SOAGY), and what does it report?

Short answer

Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). Healthcare / Medical Instruments & Supplies SEC filing business address: 4 NEW York Plaza, Floor 12, NEW York, NY, 10004. It employs 14,042 people and is led by Michael Grosse. In Q3 FY2026 it reported revenue of €921M and net income of €66M. The market values it at $22.8B.

2 · Latest results

What do the latest results show for Sartorius AG ADR (SOAGY)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €921M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€921M€66M€0.19 (diluted)
Q2 FY2026€912M€66M€0.19 (diluted)
Q1 FY2026€914M€57M€0.17 (diluted)
Q4 FY2025€919M€30M€0.09 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sartorius AG ADR (SOAGY)?

Short answer · as of

The distress and quality screens read Altman Z 10.09 · Piotroski F 6. Trailing ratios: ROE 7.8% · ROA 2.3% · current ratio 1.07 · earnings yield 1.4% · free-cash-flow yield 2.2%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SOAGY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SOAGY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sartorius AG ADR (SOAGY)?

Read these with our analysis →

What Investors Ask About Sartorius AG ADR (SOAGY) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the SOAGY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is SOAGY a good stock to buy?

Stock Expert AI does not rate SOAGY buy, sell or hold. Sartorius AG ADR has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SOAGY stock price today?

The last price recorded for Sartorius AG ADR (SOAGY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Sartorius AG do?

Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories, providing bioprocess solutions and lab products and services.

What are the key factors to evaluate for SOAGY?

Evaluate SOAGY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does SOAGY data refresh on this page?

SOAGY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SOAGY's recent stock price performance?

Sartorius AG ADR (SOAGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in bioprocess solutions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SOAGY overvalued or undervalued right now?

The trailing P/E of Sartorius AG ADR (SOAGY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SOAGY before investing?

Before investing in Sartorius AG ADR (SOAGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.